ANOTHER DOWNGRADE " Celgene Corporation (CELG) Latest Rating: SELL With A 10 Day Price Target Of: $144.45 Issued June 2nd 2014 By Sierra World Equity Review"
its a game changer....its going to be used for many things with no black box warning and no side effects that are scary....all of you need to wake and realize what this drug is...its the beginning of the end for injectible meds and it does not compromise the immune system...it will become the number selling drug in the pipeline within 5 years,doing exactly for celg what humira did for abbot labs..........i see none of you did your homework on this as its never discussed on this board yet nonsense is discussed in here daily...
Extremely fishy! I mean CELG's board meets in June to decide on a stock split...PFE is on the hunt for MORE PIPELINE (and tax benefits wuld have been the icing on the cake w/ AZN) BUT......PHARMA NEEDS BIOs PIPELINE !!!!!!!
Motley just posted a nice article suggesting PFE should buy CELG and I would add this, if PFE is serious about adding some PIPELINE....it had better get started because I suspect CELG is on a FEW BIO and PHARMA radars.................................all IMHO..............so one feable way to cap the price somewhat is to come from out of NO WHERE w/a downgrade....and YET MAINTAIN long term growth targets? LMAO! Unbelievable.....!!!!!!
Absolutely agree. He said something about lack of catalysts--absurd. CELG has over 100 Ph 2/3 clinical trials going on currently--probably too many for most to comprehend. The $710 million they paid for Crohns disease drug sounds very exciting as well. I just read the transcript from today's presentation and I am as confident as I have ever been about this company. If you get a chance, read it--you will be impressed. Jackie Fouse is amazing--we are VERY lucky to have her.
Sentiment: Strong Buy
May 28, 2014
09:14 EDT CELG Celgene position improved after Markman results, says JMP Securities
JMP Securities reports that two of the five key definition related to the composition of Celgene's Revlimid issued by a judge favored Celgene. The firm thinks the ruling weakens the threat to Celgene from NatCo, as the firm says that Celgene only needs to win one of the disputed patent claims to avert the loss of Revlimid patent protection in 2019. The firm reiterates a $205 price target and Outperform rating on Celgene.
You continue to be the contrarian. Wishing won't make it so. Didn't you learn that growing up?...Assuming for the moment you are a grown up.